Heptares Therapeutics Limited Report issue

For profit Phase 1 Phase 2
Founded: Welwyn Garden City United Kingdom (2007)
Status: Acquired by Sosei (2015)

Organization Overview

First Clinical Trial
2013
NCT02291783
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Heptares Therapeutics Limited | Heptares Therapeutics Ltd | Heptares Therapeutics Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

htl0018318 (4 trials)

Drugs in Phase 1 Trials (6)

htl0009936 (3 trials)

htl0014242 (2 trials)

htl0016878 (3 trials)

htl0022562 (1 trial)

htl0030310 (1 trial)

pasireotide (signifor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Dementia (Phase 2)

Lewy Body Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 7